These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 7398347)
1. The control of hypertension in the community. Pharmacological tratment, primary prevention or both? Wilhelmsen L; Svärdsudd K Cor Vasa; 1980; 22(1-2):5-12. PubMed ID: 7398347 [TBL] [Abstract][Full Text] [Related]
2. Lifestyle modifications to prevent and control hypertension. 1. Methods and an overview of the Canadian recommendations. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. Campbell NR; Burgess E; Choi BC; Taylor G; Wilson E; Cléroux J; Fodor JG; Leiter LA; Spence D CMAJ; 1999 May; 160(9 Suppl):S1-6. PubMed ID: 10333847 [TBL] [Abstract][Full Text] [Related]
3. Lessons from worldwide experience with hypertension control. Gyarfas I J Hum Hypertens; 1996 Feb; 10 Suppl 1():S21-5. PubMed ID: 8965282 [TBL] [Abstract][Full Text] [Related]
4. The Hypertension Optimal Treatment study and the importance of lowering blood pressure. Hansson L J Hypertens Suppl; 1999 Feb; 17(1):S9-13. PubMed ID: 10340838 [TBL] [Abstract][Full Text] [Related]
5. Nocturnal hypertension and cardiovascular risk: consequences for diagnosis and treatment. Grote L; Mayer J; Penzel T; Cassel W; Krzyzanek E; Peter JH; von Wichert P J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S26-38. PubMed ID: 7898092 [TBL] [Abstract][Full Text] [Related]
6. Lifestyle modifications to prevent and control hypertension. 5. Recommendations on dietary salt. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. Fodor JG; Whitmore B; Leenen F; Larochelle P CMAJ; 1999 May; 160(9 Suppl):S29-34. PubMed ID: 10333851 [TBL] [Abstract][Full Text] [Related]
7. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials]. Oparil S; Bakir SE Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856 [TBL] [Abstract][Full Text] [Related]
8. The future of antihypertensive treatment. Israili ZH; Hernández-Hernández R; Valasco M Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579 [TBL] [Abstract][Full Text] [Related]
9. ESH-ESC guidelines for the management of hypertension. Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473 [TBL] [Abstract][Full Text] [Related]
10. Stroke and coronary heart disease in treated hypertension -- a prospective cohort study over three decades. Almgren T; Persson B; Wilhelmsen L; Rosengren A; Andersson OK J Intern Med; 2005 Jun; 257(6):496-502. PubMed ID: 15910553 [TBL] [Abstract][Full Text] [Related]
11. Can differences in cerebral and coronary autoregulation and O2-extraction explain why antihypertensive treatment prevents stroke but not myocardial infarction? Strandgaard S; Haunsø S Ann Clin Res; 1988; 20 Suppl 48():10-3. PubMed ID: 3250314 [TBL] [Abstract][Full Text] [Related]
12. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy. Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C; Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142 [TBL] [Abstract][Full Text] [Related]
13. Lifestyle modifications to prevent and control hypertension. 3. Recommendations on alcohol consumption. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. Campbell NR; Ashley MJ; Carruthers SG; Lacourcière Y; McKay DW CMAJ; 1999 May; 160(9 Suppl):S13-20. PubMed ID: 10333849 [TBL] [Abstract][Full Text] [Related]
15. [Prevalence, treatment and control of hypertension in family practice patients in France during 1994]. Poggi L; Chamontin B; Lang T; Menard J; Chevalier H; Gallois H; Cremier O Arch Mal Coeur Vaiss; 1996 Aug; 89(8):1075-80. PubMed ID: 8949382 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306 [TBL] [Abstract][Full Text] [Related]
17. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment]. Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737 [TBL] [Abstract][Full Text] [Related]
18. Isolated systolic hypertension as a major risk factor for stroke and myocardial infarction and an unexploited source of cardiovascular prevention: a prospective population-based study. Nielsen WB; Vestbo J; Jensen GB J Hum Hypertens; 1995 Mar; 9(3):175-80. PubMed ID: 7783098 [TBL] [Abstract][Full Text] [Related]
19. [Antihypertensive therapy in stroke: acute therapy, primary and secondary prevention]. Brainin M Acta Med Austriaca; 1995; 22(3):54-7. PubMed ID: 8571753 [TBL] [Abstract][Full Text] [Related]
20. Compliance to antihypertensive drugs, salt restriction, exercise and control of systemic hypertension in hypertensive patients at Abbottabad. Ahmed N; Abdul Khaliq M; Shah SH; Anwar W J Ayub Med Coll Abbottabad; 2008; 20(2):66-9. PubMed ID: 19385461 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]